- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02731794
On-pump Beating Coronary Artery Bypass Grafting by Ventricular Assist
Inflammatory Response and Clinical Outcome After On-pump Beating Coronary Artery Bypass Grafting Using Left Ventricular Assist Versus Biventricular Assist in Patients With Severe Left Ventricle Dysfunction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Off-pump coronary artery bypass grafting (CABG) tends to have a lower incidence of postoperative complications and remarkable advantages in terms of hospital stay. However, some drawbacks include higher rates of incomplete revascularization and the hemodynamic deterioration during manipulation of the heart, more occurring in the cases of posterolateral anatomical constraints and cardiac dysfunction. It leads to urgent conversion to extracorporeal circulation (ECC) and increases the mortality. Although conventional ECC with cardioplegia arrest provides bloodless immovable field, intense systemic inflammatory response may contribute to hemodynamic unstability especially in patients already with severe cardiac dysfunction.
On-pump beating CABG, as a more comprehensive approach, not only facilitates stable hemodynamics and complete revascularization, but also supports myocardial lymphatic flow balance and decreases interstitial myocardial edema in the beating state. Especially in the high-risk patients,some findings suggested that off-pump CABG should be converted to on-pump beating CABG without hesitation, avoiding hemodynamic collapse and even catastrophic outcomes. Some investigators intentionally planned on-pump beating CABG aiming to some patients with severe left ventricle dysfunction. Furthermore, on-pump beating CABG with ECC assistance in a high-risk subgroup is also an acceptable trade-off between conventional cardioplegia and off-pump operations.
The above-mentioned ECC results about on-pump, beating-heart CABG pay much attention to the biventricular assist (BiVA). Nonetheless, much evidence also reveals that BiVA triggers an intense inflammatory response due to extracorporeal membrane lung and circuit line. Comparatively speaking, single left ventricular assist (LVA), with shorter circuit line, less priming volume and free of extracorporeal membrane lung, theoretically should reduce the inflammatory response and relative complications. As a result, aiming to the high-risk patients with severe left ventricle dysfunction, who need ECC assistance (BiVA or LVA), the investigators designed the randomized prospective study to evaluate: 1) the differences in myocardial injury as expressed by cardiac Troponin I(cTnI) and in inflammatory response by C-reactive protein (CRP), 2) the differences in the early postoperative outcomes including graft number, incidence of atrial fibrillation, in-hospital mortality and ICU stay.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Henan Provincial People' Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with severe left ventricle dysfunction with an ejection fraction (EF)≤40%, being scheduled for revascularization.
Exclusion Criteria:
- myocardial infarction within the preceding 4 weeks
- severe valve disease requiring valve replacement
- cardiac reoperations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LVA group
LVA group: left ventricular assist group.
|
In left ventricular assist group, 100 IU/kg heparin was given to activated clotting time (ACT) greater than 180 seconds.
A 22 French arterial cannula (Maquet, Irrlingen, Germany) was introduced into the ascending aorta, and a 26 French cannula (Eurosets, Medolla, Italy) into the left atrium and advanced into the left ventricle.
The two cannulas are directly connected through a short, heparin-coated circuit to a centrifuge pump (Maquet, Getinge Group, Germany).
A flow of 1.0 to 4.0 L/min/m2 is obtained and mean blood pressure was maintained 55-75 mm Hg.
Note: Both LVA group and BiVA group have the operative protocols itself,includes different prime fluid and cannula pathway.
The investigators think it is inapplicable to assign the different operative protocols to the Treatment Arm.
|
Active Comparator: BiVA group
BiVA group: Biventricular assist group.
|
In biventricular assist group, the patients were routinely heparinized with a dose of 300 IU/kg heparin to ACT greater than 480 seconds.
Cardiopulmonary bypass with a centrifuge pump (Maquet, Getinge Group, Germany) was established by 22 French aortic cannulation and 34 French two-stage venous cannula through the right atrial appendage.
The extracorporeal circuit was primed with 2000 mL of lactated Ringer's solution, albumin, 25% mannitol and 5% NaHCO3.
The flow was 1.0 to 4.0 L/min/m2 and mean blood pressure was maintained 55-75 mm Hg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of C-reactive protein (CRP)
Time Frame: up tp 72 hours
|
Serial blood samples for inflammatory response of CRP were collected at the following time points: 1: induction of anesthesia, 2: upon termination of cardiopulmonary bypass (CPB), 3: 6 hours postoperatively, 4: 24 hours postoperatively, 5: 48 hours postoperatively, 6: 72 hours postoperatively.
|
up tp 72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of atrial fibrillation
Time Frame: 10 days
|
from ICU admission to discharge
|
10 days
|
Durations of mechanical ventilation
Time Frame: 10 days
|
10 days
|
|
The number for transfused packed red cells
Time Frame: up to 10 days
|
measured by milliliter from ICU admission to discharge
|
up to 10 days
|
Partial oxygen pressure/inspired oxygen fraction (P/F)
Time Frame: up tp 10 days
|
up tp 10 days
|
|
Cardiac Troponin I (cTnI)
Time Frame: up to72 hours
|
Serial blood samples for cTnI were collected at the following time points: 1: induction of anesthesia, 2: upon termination of CPB, 3: 6 hours postoperatively, 4: 24 hours postoperatively, 5: 48 hours postoperatively, 6: 72 hours postoperatively.
|
up to72 hours
|
In-hospital mortality
Time Frame: up to 10 days
|
from ICU admission to discharge
|
up to 10 days
|
Collaborators and Investigators
Investigators
- Study Director: Zhaoyun Cheng, MD, Henan Provincial People' Hospital
Publications and helpful links
General Publications
- Lim E, Drain A, Davies W, Edmonds L, Rosengard BR. A systematic review of randomized trials comparing revascularization rate and graft patency of off-pump and conventional coronary surgery. J Thorac Cardiovasc Surg. 2006 Dec;132(6):1409-13. doi: 10.1016/j.jtcvs.2006.08.012.
- Urso S, Sadaba JR, Pettinari M. Impact of off-pump to on-pump conversion rate on post-operative results in patients undergoing off-pump coronary artery bypass. Interact Cardiovasc Thorac Surg. 2012 Feb;14(2):188-93. doi: 10.1093/icvts/ivr071. Epub 2011 Nov 28.
- Fujii T, Watanabe Y, Shiono N, Kawasaki M, Yokomuro H, Ozawa T, Hamada S, Masuhara H, Teramoto T, Hara M, Katayanagi T, Sasaki Y, Koyama N. Assessment of on-pump beating coronary artery bypass surgery performed after introduction of off-pump approach. Ann Thorac Cardiovasc Surg. 2006 Oct;12(5):324-32.
- Erkut B, Dag O, Kaygin MA, Senocak M, Limandal HK, Arslan U, Kiymaz A, Aydin A, Kahraman N, Calik ES. On-pump beating-heart versus conventional coronary artery bypass grafting for revascularization in patients with severe left ventricular dysfunction: early outcomes. Can J Surg. 2013 Dec;56(6):398-404. doi: 10.1503/cjs.018412.
- Mazzei V, Nasso G, Salamone G, Castorino F, Tommasini A, Anselmi A. Prospective randomized comparison of coronary bypass grafting with minimal extracorporeal circulation system (MECC) versus off-pump coronary surgery. Circulation. 2007 Oct 16;116(16):1761-7. doi: 10.1161/CIRCULATIONAHA.107.697482. Epub 2007 Sep 17.
- Al Jaaly E, Chaudhry UA, Harling L, Athanasiou T. Should we consider beating-heart on-pump coronary artery bypass grafting over conventional cardioplegic arrest to improve postoperative outcomes in selected patients? Interact Cardiovasc Thorac Surg. 2015 Apr;20(4):538-45. doi: 10.1093/icvts/ivu425. Epub 2014 Dec 21.
- Stassano P, Di Tommaso L, Monaco M, Iesu S, Brando G, Buonpane S, Ambrosio G, Di Benedetto G, Pepino P. Myocardial revascularization by left ventricular assisted beating heart is associated with reduced systemic inflammatory response. Ann Thorac Surg. 2009 Jan;87(1):46-52. doi: 10.1016/j.athoracsur.2008.07.098.
- Gulcan O, Turkoz R, Turkoz A, Caliskan E, Sezgin AT. On-pump/beating-heart myocardial protection for isolated or combined coronary artery bypass grafting in patients with severe left ventricle dysfunction: assessment of myocardial function and clinical outcome. Heart Surg Forum. 2005;8(3):E178-82; discussion E183. doi: 10.1532/HSF98.20041166.
- Ferrari E, Stalder N, von Segesser LK. On-pump beating heart coronary surgery for high risk patients requiring emergency multiple coronary artery bypass grafting. J Cardiothorac Surg. 2008 Jul 2;3:38. doi: 10.1186/1749-8090-3-38.
- Folliguet TA, Philippe F, Larrazet F, Dibie A, Czitrom D, Le Bret E, Bachet J, Laborde F. Beating heart revascularization with minimal extracorporeal circulation in patients with a poor ejection fraction. Heart Surg Forum. 2002;6(1):19-23. doi: 10.1532/hsf.992.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HenanICE201602
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Bypass
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedCardiopulmonary Bypass | Coronary Artery Bypass GraftingChina
-
University of VirginiaNational Institute for Biomedical Imaging and Bioengineering (NIBIB)UnknownCoronary Artery BypassUnited States
-
University of MiamiNational Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Artery BypassUnited States
-
Imperial College LondonUnknownCoronary Artery BypassUnited Kingdom
-
Foundation University IslamabadActive, not recruitingCoronary Artery BypassPakistan
-
Medistim ASACompletedRegistry for Quality Assessment With Ultrasound Imaging and TTFM in Cardiac Bypass Surgery (REQUEST)Coronary Artery BypassUnited States, United Kingdom, Netherlands, Canada, Germany, Italy
-
Maastricht University Medical CenterDutch Health Care Insurance Board (nr: 00106), Amstelveen, The NetherlandsCompleted
-
Federal University of UberlandiaCompletedCoronary Artery Bypass
-
Yale UniversityGlenn Memorial FundRecruiting
Clinical Trials on left ventricular assist
-
Abbott Medical DevicesThoratec CorporationCompletedCardiomyopathies | Ventricular Dysfunction | Heart Failure, CongestiveUnited States, Canada
-
Central Hospital, Nancy, FranceUnknownHeart Failure | Extracorporeal Membrane Oxygenation | Cardiogenic Shock | Left Ventricular Assist DeviceFrance
-
VentracorInternational Center for Health Outcomes and Innovation ResearchUnknownCardiomyopathies | End-stage Heart FailureUnited States
-
Abbott Medical DevicesThoratec Corporation; KCRI; Center for Life Sciences; EmergoCompletedAdvanced Refractory Left Ventricular Heart FailureGermany, Australia, Austria, Canada, Czechia, Kazakhstan
-
VentracorInternational Center for Health Outcomes and Innovation ResearchUnknownCardiomyopathies | End-stage Heart FailureUnited States
-
VentracorInternational Center for Health Outcomes and Innovation ResearchCompletedCardiomyopathies | End-Stage Heart FailureUnited States
-
Abbott Medical DevicesThoratec CorporationCompletedCardiomyopathies | Ventricular Dysfunction | Heart Failure, CongestiveUnited States, Canada
-
Nanjing First Hospital, Nanjing Medical UniversityNot yet recruiting
-
Heinrich SchimaTerminated
-
Shenzhen Core Medical Technology CO.,LTD.Completed